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Despite high sensitivity to chemotherapy,  the prognosis for triple-negative breast cancer (TNBC) 
remains poor because of its high rate of metastasis and low sensitivity to endocrine therapy.  CXCR4 
expression has been reported in many subtypes of human breast cancers,  but it remains unknown 
whether CXCR4 is expressed in TNBC and whether CXCR4 expression in TNBC could be a prognostic 
indicator.  TNBCs tissues were formalin ﬁxed,  paraﬃn embedded and hematoxylin-eosin (H&E) 
stained.  Immunohistochemical staining was utilized to determine the CXCR4 expression in those speci-
mens.  Statistical analyses were performed using SPSS16.0 software to reveal the correlation of CXCR4 
expression in TNBC specimens and cancer recurrence and cancer-related death.  Our results showed 
that there was a strong association between CXCR4 overexpression and both menopause and the histo-
logical cancer grade of TNBC patients (p values were separately 0.004 and 0.001).  The 5-y disease-free 
survival (DFS) and the 5-y overall survival (OS) were 57.69ｵ and 58.33ｵ for the low-CXCR4 group 
versus 42.11ｵ and 44.74ｵ for the high-CXCR4 group,  respectively (p＝0.031 and 0.048).  CXCR4 over-
expression plays an important role in triple-negative breast cancers,  and may be a predictor of poor 
prognosis.
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riple-negative breast cancer (TNBC) is a 
description often used by clinicians to describe 
tumors lacking expression of hormone receptors (HRs) 
and human epidermal growth factor receptor 2 (HER-
2).  Despite their higher sensitivity to chemotherapy 
than the other subtypes,  prognosis for TNBC remains 
poor,  because of its high rate of metastasis and low 
sensitivity to endocrine therapy [1,  2].  One study 
conducted by Liedtke et al.  clearly demonstrated that 
the poor overall survival (OS) of TNBC was derived 
from those patients with chemoresistant disease,  
unfortunately representing more than 50ｵ of TNBC 
[3].  This observation underscores the need for novel,  
biological markers and targets for patients that are not 
sensitive to existing chemotherapies.  Impairment of 
the BRCA1 pathway,  mutation of p53,  and over-
expression of epidermal growth factor receptor 
(EGFR),  caveolin-1 and so on have all been implicated 
in TNBC [4-10].  Recently,  signiﬁcantly high N-cadherin 
and TOP2A expression were shown in TNBC with 
lymphatic inﬁltration [11].
　 The fact that breast cancer is not uniform but 
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consists of several diﬀerent subtypes with diﬀerent 
molecular proﬁles,  biological behavior and risk 
proﬁles; this variability poses a challenge for its 
clinical management.  Very few of the many individual 
prognostic markers evaluated are suﬃciently powerful 
on their own to merit clinical use.  Therefore,  there 
will continuously to be a need to identify new markers 
that are prognostic and useful for therapy.  Chemokine 
(C-X-C motif) receptor 4 (CXCR4),  a seven-trans-
membrane G protein-coupled chemokine receptor,  has 
been shown to play a pivotal role in the pathogenesis 
of metastatic breast cancer [12-18].  CXCR4 on 
cancer cells could direct their migration to organs,  i.e.  
liver,  bone,  and lung,  that express high concentra-
tions of chemokine ligand 2 (CXCL-2).
　 This study was to determine the association of 
CXCR4 expression with the prognosis of TNBC,  and 
to clarify whether CXCR4 overexpression in tumor 
specimens can predict the outcomes for TNBC patients.
Materials and Methods
　 Patients and tissue specimens. Utilization of 
all 148 TNBC specimens was approved by our hospi-
tal Internal Review Board (IRB).  From January 1995 
to December 2011,  there were 719 cases of breast 
cancer with complete clinico-pathologic data including 
specimens.  All 148 cases of TNBC within that group 
were used in this study.  Clinical data of the 148 
TNBC patients were recorded prospectively,  includ-
ing the age at diagnosis,  menstruation status,  stage of 
disease,  treatment protocol,  surveillance protocol 
compliance,  and study endpoints.  Primary endpoints 
were cancer recurrence and cancer-related death.  All 
tissue samples were formalin ﬁxed and paraﬃn embed-
ded.  Hematoxylin-eosin (H&E) slides,  pathology reports,  
and other medical records were reviewed to conﬁrm 
the diagnoses as well as to establish the clinicopatho-
logic parameters of the tumors,  such as age,  meno-
pause,  tumor size,  histological grade (evaluated by 
Nottingham combined histology grade system [19,  
20]),  axillary lymph node metastasis,  and patient 
survival.  Treatment and surveillance protocols were 
standardized to ensure study homogeneity.  
Surveillance protocol consisted of a thorough physical 
examination every 3 months for 3 years,  every 6 
months in year 4 and 5,  and annually thereafter.
　 Ethics approval. The specimens in our study 
are human breast cancer samples removed by surgery 
as part of the cancer treatment.  Prior to the opera-
tion,  patients granted consent for the use of the 
excised cancer tissue in medical or scientiﬁc research.
　 Immunohistochemical staining. Cancer 
specimens were cut and transferred to adhesive-coated 
slides.  Before proceeding with the staining protocol,  
the slides were deparaﬃnized by heating at 55℃ for 
30min,  followed by 3 washes of 5min each with 
xylene,  and rehydrated by a series of 5-min washes in 
100ｵ,  90ｵ,  70ｵ ethanol and phosphate-buﬀered 
saline (PBS).  Antigen retrieval was performed by 
heating for 20min at a constant temperature of 98℃ 
in 250mL of 10-mM sodium citrate (pH6.0),  and 
endogenous peroxidase activity was blocked with 0.3ｵ 
hydrogen peroxide for 20min.  The 4 antibodies,  
introduced separately,  were rabbit polyclonal antibody 
to CXCR4 (ab2074,  Abcam,  Cambridge,  UK),  mouse 
monoclonal antibody to the estrogen receptor (ab16460,  
Abcam,  Cambridge,  UK),  and rabbit polyclonal anti-
bodies to the progesterone receptor and HER2,  
(ab68195,  ab2428; Abcam,  Cambridge,  UK); they 
were diluted 1 : 50 with goat serum separately.  After 
incubation with the primary antibodies at room tem-
perature for 1h,  the sections were washed with PBS 
3 times for 5min each,  and incubated with a goat anti-
rabbit/mouse IgG HRP polymer (ab30887 or ab2891;  
Abcam).  After 3 more washes,  DAB HRP substrate 
(ab64238; Abcam),  was added for 1 min and counter-
stained with Mayerʼs hematoxylin.  The samples were 
then dehydrated and sealed with cover slips.  Negative 
controls were performed by omitting the primary 
antibodies.  Immunostaining for estrogen receptor,  
progesterone receptor and HER2 was interpreted 
according to the Allred scoring system.  This system 
consists of a proportion score (PS: 0,  none; 1,  ＜1/100;  
2,  1/100 to 1/10; 3,  1/10 to 1/3; 4,  1/3 to 2/3;  
and 5,  ＞2/3) and an intensity score (IS: 0,  negative;  
1,  weak nuclear staining,  faintly perceptible at high-
power magniﬁcation; 2,  intermediate nuclear staining;  
and 3,  nuclei displaying strong staining with the 
appearance of an ink dot at low-power magniﬁcation).  
The PS and IS are added to obtain the total score 
(TS; range,  0,  2-8) [21],  according to the ASCO/
CAP guidance [22].  The immunostaining for CXCR4 
was semiquantiﬁed by grading the staining proportion 
and staining density: the staining proportion was 
divided into grade 0 (less than 5ｵ),  grade 1 (6-25ｵ 
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positive cells),  grade 2 (26-50ｵ positive cells),  
grade 3 (51-75ｵ positive cells) and grade 4 (more 
than 75ｵ positive cells) scored as 0,  1,  2,  3 and 4,  
respectively; and the staining density was divided into 
negative,  pale yellow,  yellow and brownish yellow,  
scored as 0,  1,  2 and 3,  respectively.  Then the 2 
scores were multiplied and the samples divided into 4 
groups based on the results: 0 negative (－); 1-4 
weakly positive (＋),  5-8 positive (＋＋) and 9-12 
strongly positive (＋＋＋).  The negative (－) and weakly 
positive (＋) results were classiﬁed as low expression 
and the positive (＋＋) and strongly positive (＋＋＋) 
results were classiﬁed as high expression.
　 Statistical analysis. Statistical analyses were 
performed using SPSS16.0 software (IBM SPSS,  
Inc.,  Armonk,  NY,  USA) according to the software 
manual (http://www.unt.edu/rss/class/Jon/SPSS_
SC/Manuals/v19/IBMｵ20SPSSｵ20Advancedｵ
20Statisticsｵ2019.pdf) to Author.  PLS put (accessed 
June,  2012-June,  2014).  Levels of CXCR4 expres-
sion,  tumor size,  and nodal status were correlated 
using the Spearman rank correlation.  Survival analy-
sis was performed using the Kaplan-Meier method,  
while the log-rank test was used to compare the curves 
and the Cox proportional hazard regression model was 
used for multivariate analysis.  Risk ratios and 95ｵ 
conﬁdence intervals (CI) were calculated from the 
model.  P values ＜0.05 were considered statistically 
signiﬁcant.
Results
　 Identiﬁcation of triple-negative breast cancer 
specimens by IHC. From 719 cases of breast 
cancer,  148 triple-negative breast cancer (TNBC) 
specimens were identiﬁed by immunohistochemical 
staining with rabbit polyclonal antibodies to estrogen 
receptor,  progesterone receptor,  and human epider-
mal growth factor receptor 2 (HER-2).  Fig.  1 shows 
representative immunohistochemical stainings of the 
estrogen receptor,  progesterone receptor,  and HER-
2.  Detailed clinicopathological characteristics of our 
148 patients are shown in Table 1.
　 CXCR4 expressions in TNBC. CXCR4 
expression was evaluated by immunohistochemical 
staining in 148 cases of TNBC.  A representative 
CXCR4 immunohistochemical staining is shown in Fig.  
2 CXCR4 overexpression was observed in varying 
degrees in the TNBC specimens; strong associations 
with CXCR4 overexpression were found for meno-
pausal status and the histological grade of cancer of 
the TNBC patients (p values,  0.004 and 0.001,  
respectively) while age (p＝0.198),  tumor size (p＝
0.134) and axillary lymph node metastasis (p＝0.484) 
were not associated with the CXCR4 overexpression 
in TNBC specimens (Table 1).
　 Correlations between CXCR4 overexpression 
and poor prognosis in TNBC. To reveal the 
correlations between the CXCR4 overexpression and 
prognosis in TNBC,  the Kaplan-Meier method was 
utilized to calculate the overall survival and disease-
free survival of the 2 groups of breast cancer patients.  
As shown by the Cox Proportional hazard model,  
CXCR4 overexpression was a signiﬁcant risk for 
cancer recurrence and cancer-related death (Table 2 
and 3).  Patients whose cancer specimens showed ele-
vated CXCR4 had a worse survival rate (Fig.  3) than 
those showing low CXCR4 levels.  The 5-y disease-
free survival (DFS) rates for the low- and high-
CXCR4 groups were 57.69ｵ and 42.11ｵ,  respec-
tively (p＝0.031).  The median DFS was 55 months 
for the low-CXCR4 group and 48 months for the high-
CXCR4 group.  The 5-y overall survival (OS) rates 
for the low- and high-CXCR4 groups were 58.33ｵ 
and 44.74ｵ,  respectively (p＝0.048); the median OS 
was 75 months for the low-CXCR4 group and 57 
months for the high-CXCR4 group.
　 To further conﬁrm that high CXCR4 overexpres-
sion in cancer specimens is a novel independent prog-
nostic indicator of a poor cancer outcome in patients 
with TNBC,  we performed a Cox proportional hazard 
model to determine the relative risks of cancer recur-
rence (Table 2) and cancer death (Table 3) between 
CXCR4 expressions and known clinicopathologic fac-
tors.  Patients whose tumors had high CXCR4 expres-
sion had a 2.02-fold and 1.97-fold increases in relative 
risk of cancer recurrence and cancer-related death,  
respectively,  compared with those whose tumors had 
low CXCR4 expression (95ｵ CI＝1.04 to 3.92; p＝
0.037; 95ｵ CI＝0.98 to 3.91; p＝0.046).  In com-
parison,  patients whose cancer had a high histological 
grade had 2.73-fold and 3.24-fold increase in relative 
risk of cancer recurrence and cancer-related death 
compared with those having a lower histological grade 
(95ｵ CI＝1.26 to 6.18; p＝0.003; 95ｵ CI＝1.14 
to 7.24; p＝0.017).
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Discussion
　 Breast Cancer (BC) is increasingly recognized as a 
heterogeneous disease exhibiting substantial varia-
tions with regard to biological behavior and requiring 
distinct therapeutic interventions.  Steroid hormone 
receptors (HRs) such as estrogen receptor (ER) and 
progesterone receptor (PgR) in concert with the onco-
gene ErbB-2/human epidermal growth factor receptor 
2 (HER-2) are critical determinants of these BC sub-
types,  and the presence of HRs is thought to indicate 
a good prognosis [23].  HER-2 expression is also 
perceived as a favorable predictive factor because 
trastuzumab has become such a potent therapeutic 
approach in HER-2-positive BC [24-26].  TNBC is 
characterized by a lack of expression of ER,  PgR and 
HER-2.  Thus,  to date,  chemotherapy remains the only 
possible therapeutic option in the adjuvant or meta-
static setting of TNBC.  A recent analysis indicates 
that TNBC carries a distinct molecular proﬁle when 
compared with HR-positive BC.  Thus,  clarifying the 
molecular events responsible for triple-negative 
aggressive behavior might assist us to better identify 
high-risk individuals and develop target-speciﬁc thera-




Fig. 1　 Representative immunohistochemical staining for estrogen receptors,  progesterone receptors,  and HER-2 expression in breast 
cancer specimens.  (A),  (C),  (E): negative expression of the estrogen receptor,  progesterone receptor,  and HER-2 by immunohistochem-
ical staining.  (B),  (D),  (F): positive expression of the estrogen receptor,  progesterone receptor,  or HER-2 by immunohistochemical 
staining.
pies.
　 The chemokine receptor CXCR4 is a 7-transmem-
brane G protein-coupled receptor that has been 
reported to be involved in the pathogenesis of meta-
static breast cancer [12-18].  CXCR4 has been found 
to be highly expressed in breast cancer cells.  Motility 
and migration of breast cancer cells expressing 
CXCR4 can be induced when they are exposed to the 
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(A) (B)
(C) (D)
Fig. 2　 Immunohistochemical staining of CXCR4 expression in the TNBC specimens in this study.  (A),  negative expression of CXCR4 
in TNBC (－); (B),  weakly positive expression of CXCR4 in TNBC (＋); (C),  positive expression of CXCR4 in TNBC (＋＋);  
(D),  strongly positive expression of CXCR4 in TNBC (＋＋＋).
Table 1　 Relationship of CXCR4 expression and clinicopatho-







　ｦ50 26 (36.11) 46 (63.89) 0.198
　＞50 20 (26.32) 56 (73.68)
Menopause
　Premenopausal 33 (41.25) 47 (62.5) 0.004
　Postmenopausal 13 (19.12) 55 (80.88)
Tumor size (cm)
　T1  8 (32.00) 17 (68.00) 0.134
　T2 18 (40.91) 26 (59.09)
　T3 15 (31.91) 32 (68.09)
　T4  5 (15.63) 27 (84.37)
Axillary lymph node metastasis
　Negative 19 (34.55) 36 (65.45) 0.484
　Positive 27 (29.03) 16 (70.97)
Histological grade
　I/II 30 (44.78) 37 (55.22) 0.001
　III 16 (19.75) 65 (80.25)
Table 2　 CXCR4 and Cancer recurrence (Cox Proportional haz-
ard model)
Factors Relative risk 95% C.I. Signiﬁcance
Age 0.73 0.31-1.57 0.28
High CXCR4 2.02 1.04-3.92 0.037
Tumor size 0.84 0.56-1.39 0.68
Histological grade 2.73 1.26-6.18 0.003
Lymph node metastasis 2.97 1.47-4.55 0.058
Table 3　 CXCR4 and Cancer-related death (Cox Proportional 
hazard model)
Factors Relative risk 95% C.I. Signiﬁcance
Age 0.84 0.37-1.63 0.39
High CXCR4 1.97 0.98-3.91 0.046
Tumor size 1.03 0.68-1.62 0.82
Histological grade 3.24 1.14-7.24 0.017
Lymph node metastasis 2.84 1.23-6.11 0.071
CXCR4 ligands,  namely,  stromal derived factor 1 
(SDF-1) [12].  The clinical utility of CXCR4 as an 
indicator of tumor metastasis has also been deﬁned 
[12-18,  27].  Chu et al.  found high CXCR4 expres-
sion in TNBC by western-blotting analysis of fresh 
frozen cancer tissue [27].  To conﬁrm whether CXCR4 
is an important factor in the clinical setting of TNBC,  
we performed immunohistochemical staining for 
CXCR4 on paraﬃn-embedded,  formalin-ﬁxed TNBC 
tissues,  and then evaluated its role in triple-negative 
breast cancer prognosis.  We found high levels of 
CXCR4 expression in the primary triple-negative 
breast cancers.  Therefore,  CXCR4 may be an impor-
tant parameter for TNBCs.  CXCR4 was also a strong 
indicator of TNBC outcome: high CXCR4 expression 
was associated with a signiﬁcantly worse disease-free 
survival and overall survival than tumors with low 
CXCR4 expression (Fig.  3 and Table 2-3),  as indi-
cated by the univariate analysis model (Kaplan-Meier 
and log-rank test) and the multivariate Cox propor-
tional hazard model (Tables 4 and 5).  It has been 
reported that CXCR4 regulates tumor cell growth,  
migration and metastases in lungs,  brains and bones 
[12-16] although the details about metastases other 
than lymph-node metastases are not complete.  This 
migration might also be the main cause of the poor 
outcome of TNBC.  Therefore,  in the future it will be 
helpful to research the correlation of CXCR4 overex-
pression with metastases in lungs,  bones or other 
organs.  In this study,  we noted that both CXCR4 
overexpression and histological grade were signiﬁcant 
predictors of cancer recurrence and cancer-related 
death on multivariate analysis (p＝0.037 and 0.046,  
Tables 2 and 3),  as has also been observed by others 
[27],  but there was no correlation of CXCR4 overex-
pression with lymph node metastases (p＝0.058 and 
0.071) (Table 1).  Whether this is due to a statistical 
limitation or indicates a real biological phenomenon is 
not known.
　 In conclusion,  our ﬁndings indicate that CXCR4 
overexpression plays an important role in triple-nega-
tive breast cancers,  and may be an indicator of poor 
prognosis.
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